PRAX
Praxis Precision Medicines, Inc.
Next earnings Aug 3, 2026 · consensus $-3.72 EPS
Last earnings -1.4% on 2026-05-07
$327.86
▲ +6.12%$327.86▲ +674.35%
over 1Y
L $37.71EODHDH $357.13
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+6.1%
1W+16.1%
1M-6.5%
3M+8.3%
YTD+14.5%
1Y+674.4%
Avoid
Conviction
Horizon
Long (>12mo)
Street · 23 analysts
Buy
A pre-revenue clinical-stage biotech burning $249M a year, richly priced on trial hopes — a binary bet, not an investment.
Praxis Precision Medicines is a clinical-stage biopharmaceutical company developing CNS/neurology drug candidates, and by its own description in the 10-K, 'investing in our common stock involves a high degree of risk' and 'you might lose all or part of your investment.' It has no approved products and generated $0 of revenue in FY2025 (after token $2.45M and $8.55M in the prior two years from collaboration/grant income), while net loss widened to -$303M and R&D spending jumped 75.3% to $267M as it advanced trials. The accumulated deficit is now $1.1B, and operating cash burn was -$249M for the year.
Sources: SEC EDGAR (CIK 0001689548, latest 10-Q filed 2026-05-07) · EODHD · analysis by claude-code · as of 6/21/2026, 9:02:53 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.